Current Clinical Trials

Phase I Study of the safety, Pharmacokinetic and Pharmacodynamic Properties of Intravenously Administered APG-1252 in Patients with Small Cell Lung Cancer (SCLC) or other Solid Tumors

Phase I, dose escalation study of ALX148 in patients with advanced solid tumors or lymphoma examining safety, pharmacokinetics and tolerability. NOW IN COMBINATION PHASE II WITH PEMBROLIZUMAB, RITUXIMAB AND TRASTUZUMAB

A Phase Ia/IIa Cohort Dose Escalation Trial to Determine the safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID100, an Anti-Human Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Linked to the Maytansinoid DM1 in Patients with Advanced or Metastatic Solid Tumors of Epithelial Origin.

A Phase I Cohort Dose-Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of AVID 200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients with Advanced or Metastatic Solid Tumor Malignancies

A Phase Ib Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors

A Phase I/II, First-in-Humans, Open-Label, Dose-Escalation Study of MGC018 (Anti-B7-H3 Antibody Drug Conjugate) Alone and in Combination with MGA012 (Anti-PD-1 Antibody) in Patients with Advanced Solid Tumors

A Multinational, Multicenter, Randomized, Phase III Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane

Principle Investigator: Dr. Vander Woude

A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy

Principle Investigator: Dr. Chen

Registry of Guardant360® Use and Outcomes In People With Advanced Cancer (GEODE)

Principle Investigator: Dr. Santos

A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in adult patients with Advanced Non-Small Cell Lung Cancer (NSCLC)

Principle Investigator: Dr. Chen

RESILIENT: A Randomized, Open Label Phase III Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

Principle Investigator: Dr. Chen

A Phase III, Randomized, Multi-Center, Open-Label, Active-Comparator Controlled Trial to Evaluate the Efficacy and Safety of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Principle Investigator: Dr. Wong

Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Primary Investigator: Dr. O’Rourke

Expanded access to mepolizumab for patients with hypereosinophilic syndrome

Principal Investigator: Dr. Gribbin

A Phase III Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) with VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

Principle Investigator: Dr. Brinker

A Phase II, randomized, multi-center, double-blind, comparative global study to determine the efficacy and safety of Durvalumab in combination with Olaparib for first-line treatment in platinum-ineligible patients with unresectable Stage IV Urothelial Cancer.

Priciple Investigator: Dr. Chandana

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer.

Principle Investigator: Dr. Batts

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors from twelve primary cancer diagnoses: breast, lung, colorectal, prostate, bladder, uterine, kidney and renal pelvis, pancreatic, liver, stomach, ovarian, esophageal

Principle Investigator: Dr. Chandana

A Phase II, Multicenter, Open-label, Safety and Efficacy Study of Xermelo plus First-line Chemotherapy (Cis/Gem) in Patients with Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC).

Principle Investigator: Dr. Chandana

PANOVA-3: Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant with Gemcitabine and Nab-paclitaxel

Principle Investigator: Dr. Chandana

A Phase III Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib vs. Cis/Gem in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations.

Principal Investigator: Dr. Chandana